Zydus Cadilla seeks DCGI's approval to undertake clinical trials for monoclonal antibodies cocktail

Pharmaceutical Company Zydus Cadilla has sought Drug Controller General of India's(DCGI) approval to undertake clinical trials for monoclonal antibodies cocktail that can neutralise Covid infection. India's leading Indian Pharmaceutical company Zydus Cadilla Healthcare has announced biological therapy ZRC-3308 for the treatment of mild COVID-19 symptoms. ZRC-3308 is a cocktail of two anti-SARS-CoV-2 monoclonal antibodies.   Managing Director of Cadila Healthcare Limited, Dr. Sh...